Motus GI (NASDAQ:MOTS) announced its earnings results on Friday. The company reported ($0.26) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.29) by $0.03, Fidelity Earnings reports.
NASDAQ:MOTS remained flat at $$2.66 on Friday. The company’s stock had a trading volume of 48,641 shares, compared to its average volume of 120,065. The company has a debt-to-equity ratio of 0.05, a current ratio of 6.36 and a quick ratio of 6.31. The business has a 50 day moving average price of $3.05. The firm has a market cap of $57.06 million, a PE ratio of -2.16 and a beta of 1.60. Motus GI has a twelve month low of $2.34 and a twelve month high of $7.40.
In other Motus GI news, Chairman David P. Hochman purchased 10,000 shares of the firm’s stock in a transaction on Monday, July 1st. The shares were acquired at an average cost of $3.00 per share, with a total value of $30,000.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Life Sciences Maste Perceptive purchased 1,000,000 shares of the firm’s stock in a transaction on Thursday, June 27th. The shares were acquired at an average cost of $3.00 per share, for a total transaction of $3,000,000.00. The disclosure for this purchase can be found here. Over the last three months, insiders have acquired 2,059,332 shares of company stock worth $6,179,896. Insiders own 18.14% of the company’s stock.
Motus GI Company Profile
Motus GI Holdings, Inc operates as a medical technology company to enhance the endoscopy outcomes and experiences in the United States and Israel. It focuses on the development and commercialization of the Pure-Vu system to enhance the colonoscopy experience and assist in the early detection and prevention of colorectal cancer and other diseases of the rectum and colon.
See Also: Net Asset Value
Receive News & Ratings for Motus GI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Motus GI and related companies with MarketBeat.com's FREE daily email newsletter.